Study at a glance
What controls vitamin D activity?
This page brings together studies of how the body balances making active vitamin D with breaking it down. Most of the evidence comes from mice, cells and small tissue models grown in the laboratory. The researchers examined hormone signals, the parts of DNA that control enzyme production, and what happens when an enzyme is removed from particular tissues.
How did hormones and tissues control vitamin D activity?
Active vitamin D can increase production of CYP24A1, an enzyme that helps break it down. This helps limit how long its signal lasts. In the kidney, parathyroid hormone generally increases vitamin D activation and reduces breakdown. Another hormone, FGF23, usually has the opposite effect. However, one mouse experiment found no measurable FGF23 effect under the conditions tested. Other mouse experiments showed that the kidney has a major role in controlling vitamin D compounds in the blood. The intestine can control vitamin D activity locally without causing the same changes in blood levels.
Do vitamin D blood levels show what happens in every tissue?
Vitamin D breakdown is an adjustable part of the control system. Hormones and different tissues can change the balance between activation and breakdown. Blood levels alone do not show that every tissue has the same vitamin D exposure. These experiments help explain how the system works, but the size of the effects in laboratory models cannot be assumed to be the same in people.
Read the full article below ↓Clearance is regulated together with activation
Vitamin D clearance is not a fixed background process. In the kidney, the enzyme that destroys vitamin D metabolites, CYP24A1, is regulated in reciprocal relationship with CYP27B1, the enzyme that generates active 1,25(OH)2D from 25(OH)D. Endocrine signals therefore change both sides of the balance: how much active hormone is made and how rapidly precursor or active hormone is directed toward catabolism within the coupled CYP27B1 and CYP24A1 enzyme pathways.
The resulting feedback architecture involves calcitriol itself, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), renal cell identity and tissue-specific enhancer control.
Calcitriol creates direct negative feedback through VDR
One of the clearest feedback loops begins with 1,25(OH)2D itself. VDR/RXR complexes bind regulatory elements associated with CYP24A1 and stimulate transcription of the catabolic enzyme. Meyer, Goetsch and Pike mapped a downstream cluster of regulatory enhancers that contributes materially to this induction.
This arrangement allows the active hormone to accelerate its own inactivation. Rising calcitriol signalling therefore does not simply amplify downstream transcription; it also induces machinery that shortens the lifetime of the signal.
PTH and FGF23 push renal metabolism in opposite directions
Renal vitamin D metabolism is also coupled to mineral homeostasis. PTH tends to increase active vitamin D availability by stimulating Cyp27b1 and suppressing Cyp24a1. FGF23 generally acts in the opposite direction, reducing activation while increasing catabolic pressure through Cyp24a1.
Meyer and colleagues showed that this regulation depends on chromatin architecture rather than one generic promoter switch. Their work identified regulatory regions that respond differently in kidney and nonrenal tissues and demonstrated, using enhancer deletion, that distinct downstream elements carry specific regulatory jobs.
The proximal tubule is a major PTH-responsive control site
Yoon and colleagues strengthened the cellular mechanism by localising much of the PTH-responsive programme to S1 proximal-tubule cells. Their work identified a PTH/salt-inducible kinase signalling axis that increases Cyp27b1 while lowering Cyp24a1.
This reciprocal response is physiologically important because it coordinates synthesis and clearance rather than adjusting one enzyme in isolation. When PTH signals a need for greater calcium support, renal metabolism is shifted toward greater active-hormone availability by both increasing activation and reducing catabolism.
FGF23 regulation is real but not unconditional
A useful qualification comes from experiments that did not reproduce an FGF23 effect under the tested conditions. In a 2018 murine study, the chosen FGF23 exposure did not measurably alter renal or extrarenal hydroxylase expression, while 1,25(OH)2D still strongly increased renal Cyp24a1 and reduced Cyp27b1.
This does not erase the broader FGF23 literature. It does show that FGF23 responsiveness depends on dose, timing, tissue and experimental context. The scientifically defensible description is therefore that FGF23 generally promotes a renal shift toward reduced activation and increased catabolism, not that every FGF23 exposure must produce the same measurable Cyp24a1 response.
Renal and nonrenal clearance are not governed identically
Meyer and colleagues also demonstrated that the renal regulatory architecture cannot simply be projected onto every tissue. Enhancer dependence and hormone responsiveness differ between kidney and nonrenal sites. This matters because CYP24A1 is expressed outside the kidney, where it can regulate local vitamin D exposure even when systemic circulating concentrations are controlled elsewhere, a distinction developed more broadly in vitamin D metabolism at the cellular level.
The distinction between systemic and local clearance became clearer in tissue-specific deletion experiments. Fuchs and colleagues compared global, kidney-specific and intestine-specific Cyp24a1 loss in mice. Removing Cyp24a1 globally or from kidney produced marked systemic effects consistent with impaired whole-body catabolic control. Intestinal deletion, by contrast, altered local vitamin D activity and mineral-related responses without reproducing the same systemic metabolite phenotype.
Kidney and intestine therefore perform different clearance jobs
The tissue-deletion evidence supports a hierarchy of function rather than one uniform distributed clearance system. Renal CYP24A1 is a major determinant of systemic vitamin D metabolite handling. Intestinal CYP24A1 can regulate local tissue exposure and downstream responses more autonomously.
This local-versus-systemic distinction prevents two common errors: assuming that every tissue contribution to CYP24A1 equally determines circulating vitamin D status, and assuming that a normal systemic concentration guarantees identical intracellular vitamin D exposure in every tissue.
How activation and degradation form a feedback system
Taken together, these experiments describe a dynamic control loop. 25(OH)D can be activated by CYP27B1 or directed toward oxidation by CYP24A1. Calcitriol induces CYP24A1 through VDR-mediated transcription, thereby creating negative feedback. PTH shifts renal metabolism toward activation and away from degradation, while FGF23 generally pushes in the opposite direction. Tissue-specific chromatin and signalling determine how strongly those inputs are expressed in a given organ.
Clearance is therefore not an endpoint that occurs only after vitamin D signalling is complete. It is part of the control system that determines signal amplitude, duration and tissue exposure. This regulatory context is also relevant when interpreting Vitamin D Thresholds vs Targets.
What this evidence establishes and what it does not
- Calcitriol induces CYP24A1 through VDR/RXR-dependent regulatory regions, creating direct negative feedback.
- Renal PTH signalling suppresses Cyp24a1 while promoting Cyp27b1.
- FGF23 generally favours the opposite renal direction but its measured effect is context dependent.
- Kidney and nonrenal tissues do not use identical CYP24A1 regulatory architecture.
- Renal CYP24A1 has a major systemic clearance role, whereas intestinal CYP24A1 can exert important local control.
- Reciprocal activation-versus-clearance regulation is tissue and signal dependent rather than a single universal switch.
Most mechanistic evidence in this set comes from mouse, cell and organoid systems. These models establish regulatory architecture and causal tissue roles, but they do not justify treating every quantitative response as identical in humans.
Primary evidence and publication details
Meyer MB, Lee SM, Carlson AH, et al. A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. J Biol Chem. 2019;294:14467-14481.
Meyer MB, Goetsch PD, Pike JW. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem. 2010;285:15599-15610.
Yoon SH, Meyer MB, Arevalo C, et al. A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis. J Clin Invest. 2023;133:e163627.
Fuchs MAA, Grabner A, Shi M, et al. Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice. J Clin Invest. 2025;135:e179882.
Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3. Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3. 2018.
Related reading
Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Severe hypercalcemia is often associated with uncontrolled malignancy through several mechanisms.
Original paper ↗Read more →Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
A randomized, controlled open-label study was undertaken in 60 HD patients with serum iPTH > 1000 pg/mL or persistently high iPTH ≥ 600 pg/mL even after >3 months of calcitriol (3 μg/week).
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia
Hypercalcemic hyperparathyroidism has been associated with poor outcomes after kidney transplantation (KTx).
Original paper ↗Read more →Gender specific association of parathyroid hormone and vitamin D with metabolic syndrome in population with preserved renal function
The association of parathyroid hormone (PTH) and vitamin D with Metabolic syndrome (MetS) was evaluated using representative data from the Korean population.
Original paper ↗Read more →MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma
To investigate the expression of miR-125b and vitamin D receptor (VDR) in renal cell carcinoma (RCC) and assess the biological function of miR-125b in RCC.
Original paper ↗Read more →Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years
Chronic kidney disease (CKD) is a prevalent pathological condition worldwide.
Original paper ↗Read more →Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes
This study examines prognostic implications of PTH reduction from different etiologies.
Original paper ↗Read more →Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce.
Original paper ↗Read more →The vitamin D receptor gene ApaI polymorphism is associated with increased risk of renal cell carcinoma in Chinese population
This study aimed to investigate the genetic association of VDR polymorphisms with renal cell carcinoma (RCC) risk in the Chinese population.
Original paper ↗Read more →Vitamin D receptor suppresses proliferation and metastasis in renal cell carcinoma cell lines via regulating the expression of the epithelial Ca2+ channel TRPV5
The aim of this study was to elucidate whether VDR could regulate the expression of TRPV5 and affect proliferation and metastasis in RCC.
Original paper ↗Read more →Vitamin D Status among Thai School Children and the Association with 1,25-Dihydroxyvitamin D and Parathyroid Hormone Levels
Only 4% (21 of 529) participants had a serum 25(OH)D level below 50 nmol/L.
Original paper ↗Read more →Tissue-Specific VDR Physiology: Knockout and Rescue Evidence
Causal knockout and rescue evidence showing how tissue-specific VDR expression contributes to calcium, bone and whole-body physiology.
Read more →Relationship Between Total 25-Hydroxyvitamin D and Parathyroid Hormone Concentrations During Early Gestation in Indian Women
The inverse relationship between 25(OH)D and parathyroid hormone (PTH) concentrations was examined to define the breakpoint at which PTH was maximally suppressed using a segmented regression analysis.
Original paper ↗Read more →Serum 25-hydroxyvitamin D and parathyroid hormone in relation to plasma B-type natriuretic peptide: the Hoorn Study
Therefore, we investigated whether lower 25-hydroxyvitamin D (25(OH)D) and higher PTH are cross sectionally and after 8 years of follow-up associated with higher B-type natriuretic peptide (BNP) levels in older men and women.
Original paper ↗Read more →Serum Parathyroid Hormone, 25-Hydroxyvitamin D, and Risk of Alzheimer’s Disease: A Mendelian Randomization Study
We conducted Mendelian randomization analyses to investigate the associations of serum parathyroid hormone (S-PTH) and serum 25-hydroxyvitamin D (S-25OHD) concentrations with Alzheimer’s disease (AD).
Original paper ↗Read more →The Role of Calcium, 25-Hydroxyvitamin D, and Parathyroid Hormone in Irritable Bowel Syndrome: A Bidirectional Two-Sample Mendelian Randomization Study
Therefore, we aimed to explore the bidirectional causal effects among serum calcium, Vit-D, PTH, and IBS at the genetic level by a two-sample Mendelian randomization (MR) analysis of the datasets from IEU OpenGWAS database.
Original paper ↗Read more →Three-year follow-up of serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in nursing home residents who had received 12 months of daily bread fortification with 125 μg of vitamin D3
We conducted a single-arm clinical trial in institutionalized seniors, on the effects of high-dose vitamin D3-fortified bread daily intake (clinicaltrials.gov registration NCT00789503).
Original paper ↗Read more →Threshold of 25(OH)D and consequently adjusted parathyroid hormone reference intervals: data mining for relationship between vitamin D and parathyroid hormone
By recruiting reference population, we aimed to (1): estimate the 25(OH)D threshold that maximally inhibits the PTH, which can be defined as the cutoff value for vitamin D sufficiency; (2) establish the PTH reference interval (RI) in population with sufficient vitamin D.
Original paper ↗Read more →Original sources
A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues
Published in J Biol Chem (2019).
Publication details
Meyer MB, Lee SM, Carlson AH, et al. A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. J Biol Chem. 2019;294:14467-14481.
A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3
Published in J Biol Chem (2010).
Publication details
Meyer MB, Goetsch PD, Pike JW. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem. 2010;285:15599-15610.
A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Publication details
Yoon SH, Meyer MB, Arevalo C, et al. A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis. J Clin Invest. 2023;133:e163627.
Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice
Vitamin D regulates mineral homeostasis.
Publication details
Fuchs MAA, Grabner A, Shi M, et al. Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice. J Clin Invest. 2025;135:e179882.
Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3
Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3.
Publication details
Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3. Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3. 2018.